{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:52:02Z","timestamp":1790092322369,"version":"4.0.1"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00969","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T04:35:52Z","timestamp":1589949352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies"],"prefix":"10.3389","volume":"11","author":[{"given":"Takashi Kei","family":"Kishimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nrd3040","article-title":"Market watch: sales of biologics to show robust growth through to 2013","volume":"8","author":"Goodman","year":"2009","journal-title":"Nat. Rev. Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.12688\/f1000research.9970.1","article-title":"Recent advances in (therapeutic protein) drug development","volume":"6","author":"Lagasse","year":"2017","journal-title":"F1000Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nrd3974","article-title":"Challenges and approaches for the development of safer immunomodulatory biologics","volume":"12","author":"Sathish","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/nrrheum.2013.4","article-title":"Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis","volume":"9","author":"van Schouwenburg","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"B5","first-page":"15","article-title":"Immunogenicity of biological therapeutics: a hierarchy of concerns","volume":"112","author":"Rosenberg","year":"2003","journal-title":"Dev Biol"},{"key":"B6","first-page":"560","article-title":"The immunogenicity of therapeutic proteins","volume":"9","author":"Schellekens","year":"2010","journal-title":"Discov Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2012","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2002","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/jth.12634","article-title":"Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa","volume":"12","author":"Lentz","year":"2014","journal-title":"J Thromb Haemost."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","article-title":"Current progress in innovative engineered antibodies","volume":"9","author":"Strohl","year":"2018","journal-title":"Protein Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1208\/s12248-014-9587-6","article-title":"New FDA draft guidance on immunogenicity","volume":"16","author":"Parenky","year":"2014","journal-title":"AAPS J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrrheum.2010.153","article-title":"Therapy: Immunogenicity of biologic therapies-we need tolerance","volume":"6","author":"Krieckaert","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.coi.2015.05.005","article-title":"Engineering antigen-specific immunological tolerance","volume":"35","author":"Kontos","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.3389\/fimmu.2019.03078","article-title":"Factor VIII: perspectives on immunogenicity and tolerogenic strategies","volume":"10","author":"Scott","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41587-019-0015-4","article-title":"Antigen-specific therapeutic approaches for autoimmunity","volume":"37","author":"Serra","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fimmu.2018.00230","article-title":"Nanoparticles for the induction of antigen-specific immunological tolerance","volume":"9","author":"Kishimoto","year":"2018","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1801419","DOI":"10.1002\/adhm.201801419","article-title":"Engineering immune tolerance with biomaterials","volume":"8","author":"Gammon","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"B20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.nano.2018.10.001","article-title":"Overcoming challenges in treating autoimmuntity: development of tolerogenic immune-modifying nanoparticles","volume":"18","author":"Pearson","year":"2019","journal-title":"Nanomedicine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.tibtech.2018.05.008","article-title":"Evaluating and mitigating the immunogenicity of therapeutic proteins","volume":"36","author":"Sauna","year":"2018","journal-title":"Trends Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/B978-0-12-380995-7.00004-5","article-title":"How tolerogenic dendritic cells induce regulatory T cells","volume":"108","author":"Maldonado","year":"2010","journal-title":"Adv Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","article-title":"Tolerogenic dendritic cells","volume":"21","author":"Steinman","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1073\/pnas.131202998","article-title":"How the immune system works to protect the host from infection: a personal view","volume":"98","author":"Janeway","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6445-1_1","article-title":"Overview of vaccine adjuvants: introduction, history, current status","volume":"1494","author":"Shah","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-3-540-71029-5_10","article-title":"Use of rapamycin in the induction of tolerogenic dendritic cells","volume":"188","author":"Fischer","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1111\/j.1538-7836.2009.03548.x","article-title":"Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells","volume":"7","author":"Nayak","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3389\/fmicb.2011.00244","article-title":"Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B","volume":"2","author":"Nayak","year":"2011","journal-title":"Front Microbiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/j.1538-7836.2011.04351.x","article-title":"Induction of tolerance to factor VIII by transient co-administration with rapamycin","volume":"9","author":"Moghimi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur J Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2006.01.006","article-title":"in vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles","volume":"112","author":"Reddy","year":"2006","journal-title":"J Control Release"},{"key":"B34","doi-asserted-by":"publisher","first-page":"E156","DOI":"10.1073\/pnas.1408686111","article-title":"Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance","volume":"112","author":"Maldonado","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B35","doi-asserted-by":"publisher","first-page":"E733","DOI":"10.1073\/pnas.1717063115","article-title":"Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity","volume":"115","author":"Mazor","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"key":"B37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1163\/156856201744425","article-title":"Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic\/glycolic acid polymers. Part II: biodegradation","volume":"12","author":"Wu","year":"2001","journal-title":"J Biomater Sci Polym Ed"},{"key":"B38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J Pharm Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","article-title":"Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets","volume":"186","author":"Michalek","year":"2011","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood-2007-06-094482","article-title":"Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells","volume":"111","author":"Zeiser","year":"2008","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fimmu.2014.00409","article-title":"Nutrient sensing via mTOR in T cells maintains a tolerogenic microenvironment","volume":"5","author":"Howie","year":"2014","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e5994","DOI":"10.1371\/journal.pone.0005994","article-title":"Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin","volume":"4","author":"Strauss","year":"2009","journal-title":"PLoS ONE"},{"key":"B43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0041-1345(96)00008-5","article-title":"Sirolimus: a new agent for clinical renal transplantation","volume":"29","author":"Kahan","year":"1997","journal-title":"Transplant Proc"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e92888","DOI":"10.1371\/journal.pone.0092888","article-title":"Inhibition of calcineurin abrogates while inhibition of mTOR promotes regulatory T cell expansion and graft-versus-host disease protection by IL-2 in allogeneic bone marrow transplantation","volume":"9","author":"Satake","year":"2014","journal-title":"PLoS ONE"},{"key":"B45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cellimm.2015.11.004","article-title":"Tolerogenic nanoparticles to induce immunologic tolerance: prevention and reversal of FVIII inhibitor formation","volume":"301","author":"Zhang","year":"2016","journal-title":"Cell Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fimmu.2018.00281","article-title":"Tolerogenic nanoparticles induce antigen-specific regulatory T cells and provide therapeutic efficacy and transferrable tolerance against experimental autoimmune encephalomyelitis","volume":"9","author":"LaMothe","year":"2018","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat Nanotechnol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1038\/psp.2013.33","article-title":"Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content","volume":"2","author":"Emoto","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/1535-7163.MCT-15-0720","article-title":"The enigma of rapamycin dosage","volume":"15","author":"Mukhopadhyay","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.immuni.2015.06.007","article-title":"T cell receptor cross-reactivity between similar foreign and self peptides influences naive cell population size and autoimmunity","volume":"42","author":"Nelson","year":"2015","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0952-7915(98)80162-3","article-title":"Long-lived plasma cells: a mechanism for maintaining persistent antibody production","volume":"10","author":"Slifka","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgmr.2017.03.005","article-title":"A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease","volume":"13","author":"Lim","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/hae.12970","article-title":"The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline","volume":"22","author":"Aledort","year":"2016","journal-title":"Haemophilia"},{"key":"B55","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/00063030-200822020-00005","article-title":"Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders","volume":"22","author":"Croom","year":"2008","journal-title":"BioDrugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/hae.12049","article-title":"Inhibitors: our greatest challenge. Can we minimize the incidence?","volume":"19","author":"Kruse-Jarres","year":"2013","journal-title":"Haemophilia."},{"key":"B58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"B60","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B61","unstructured":"Update of SEL-212 phase 2 clinical data in symptomatic gout patients: SVP-Rapamycin combined with pegadricase mitigates immunogenicity and enables sustained reduction of serum uric acid levels, low rate of gout flares and monthly dosing70\n            SandsE\n            KivitzAJ\n            DeHannW\n            JohnstonL\n            KishimotoTK\n          Arthritis Rheumatol.2018"},{"key":"B62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/03946320140270S103","article-title":"Adalimumab in the treatment of immune-mediated diseases","volume":"27","author":"Lapadula","year":"2014","journal-title":"Int J Immunopathol Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e00380","DOI":"10.1002\/prp2.380","article-title":"Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects","volume":"6","author":"Hillson","year":"2018","journal-title":"Pharmacol Res Perspect."},{"key":"B64","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/bcp.13039","article-title":"Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira (R) in healthy subjects","volume":"82","author":"Hyland","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/bcp.13245","article-title":"Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab\/Humira, in healthy subjects","volume":"83","author":"Puri","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/toxins11010020","article-title":"Pseudomonas exotoxin immunotoxins and anti-tumor immunity: from observations at the patient's bedside to evaluation in preclinical models","volume":"11","author":"Leshem","year":"2019","journal-title":"Toxins."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2019","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.ajpath.2018.04.016","article-title":"Strategies to reduce the immunogenicity of recombinant immunotoxins","volume":"188","author":"Mazor","year":"2018","journal-title":"Am J Pathol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/imr.12390","article-title":"Immunogenicity of therapeutic recombinant immunotoxins","volume":"270","author":"Mazor","year":"2016","journal-title":"Immunol Rev"},{"key":"B70","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children","volume":"144","author":"Kishnani","year":"2004","journal-title":"J Pediatr"},{"key":"B71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/gim.2015.6","article-title":"CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy","volume":"17","author":"Berrier","year":"2015","journal-title":"Genet Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41436-018-0270-7","article-title":"An immune tolerance approach using transient low-dose methotrexate in the ERT-naive setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease","volume":"21","author":"Kazi","year":"2019","journal-title":"Genet Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"B77","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1089\/hum.2015.025","article-title":"Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success\u2013a personal perspective","volume":"26","author":"Hastie","year":"2015","journal-title":"Hum Gene Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu Rev Virol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol Ther"},{"key":"B82","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.immuni.2019.01.020","article-title":"Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer","volume":"50","author":"Wing","year":"2019","journal-title":"Immunity"},{"key":"B83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/imr.12175","article-title":"Lineage stability and phenotypic plasticity of Foxp3(+) regulatory T cells","volume":"259","author":"Hori","year":"2014","journal-title":"Immunol Rev"},{"key":"B84","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/imr.12173","article-title":"Once a Treg, always a Treg?","volume":"259","author":"Sawant","year":"2014","journal-title":"Immunol Rev"},{"key":"B85","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0952-7915(02)00406-5","article-title":"Making and breaking tolerance","volume":"14","author":"Ohashi","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"30842","DOI":"10.1038\/srep30842","article-title":"The aged lymphoid tissue environment fails to support naive T cell homeostasis","volume":"6","author":"Becklund","year":"2016","journal-title":"Sci Rep"},{"key":"B87","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1196\/annals.1354.018","article-title":"Naive T cells in the elderly: are they still there?","volume":"1067","author":"Pfister","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/WNL.0b013e318233b240","article-title":"A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS","volume":"77","author":"Freedman","year":"2011","journal-title":"Neurology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"367.1","DOI":"10.1136\/annrheumdis-2017-eular.3548","article-title":"THU0422 SEL-212: enhanced serum uric acid control in hyperuricemic patients through selective mitigation of anti-drug antibodies against pegsiticase","volume":"76","author":"Sands","year":"2017","journal-title":"Ann Rheum Dis."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T04:35:59Z","timestamp":1589949359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":89,"alternative-id":["10.3389\/fimmu.2020.00969"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00969","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"article-number":"969"}}